{
    "N/R/U": null,
    "Applicant": "AbbVie Inc.",
    "BLA Number": "761105",
    "Proprietary Name": "Skyrizi",
    "Proper Name": "risankizumab-rzaa",
    "BLA Type": "351(a)",
    "Strength": "360MG/2.4ML (150MG/ML)",
    "Dosage Form": "Injection ",
    "Route of Administration": "Subcutaneous",
    "Product Presentation": "Single-Dose Cartridge",
    "Marketing Status": "Rx",
    "Licensure": "Licensed",
    "Approval Date": "June 16, 2022",
    "Ref. Product Proper Name": null,
    "Ref. Product Proprietary Name": null,
    "Supplement Number": "16",
    "Submission Type": "Supplement",
    "License Number": "1889",
    "Product Number": "005",
    "Center": "CDER",
    "Date of First Licensure": null,
    "Exclusivity Expiration Date": null,
    "First Interchangeable Exclusivity Exp. Date": null,
    "Ref. Product Exclusivity Exp. Date": null,
    "Orphan Exclusivity Exp. Date": null
}